Europe’s medical devices industry sees a rise of 12.7% in deal activity in Q3 2019

23 November 2019 (Last Updated November 22nd, 2019 13:14)

Europe’s medical devices industry sees a rise of 12.7% in deal activity in Q3 2019

Europe’s medical devices industry saw a rise of 12.7% in overall deal activity during Q3 2019, when compared to the four-quarter average, according to GlobalData’s deals database.

  • Embed this chart

    Embed this chart into your website

    Copy and paste the code below into your website to display the chart.

A total of 80 deals worth $627.42m were announced for the region during Q3 2019, against the last four-quarter average of 71 deals.

Of all the deal types, venture financing saw most activity in Q3 2019 with 40, representing a 50% share for the region.

In second place was M&A with 29 deals, followed by private equity deals with 11 transactions, respectively capturing a 36.3% and 13.8% share of the overall deal activity for the quarter.

In terms of value of deals, venture financing was the leading category in Europe’s medical devices industry with $539.4m, while M&A and private equity deals totalled $80.26m and $7.76m, respectively.

Europe medical devices industry deals in Q3 2019: Top deals

The top five medical devices deals accounted for 63% of the overall value during Q3 2019.

The combined value of the top five medical devices deals stood at $395.18m, against the overall value of $627.42m recorded for the quarter.

The top five medical devices industry deals of Q3 2019 tracked by GlobalData were:

1) Cambridge Innovation Capital, Escala Capital Investments Cyprus, LGT Impact Ventures, Silk Road Fund and Watrium’s $242.67m venture financing of CMR Surgical

2) The $47.03m venture financing of Quanta Dialysis Technologies by btov Partners, Seroba Life Sciences and Wellington Partners

3) BNP Paribas Fortis Private Equity, Capricorn Venture Partners, Earlybird Venture Capital GmbH & Co, Gimv, Life Sciences Partners, Societe Regionale d’Investissement de Wallonie and The Federal Holding and Investment’s $44.03m venture financing of iSTAR Medical

4) The $33.59m acquisition of Cytena by Cellink

5) CellaVision’s acquisition of RAL Diagnostics for $27.85m.

Verdict deals analysis methodology

This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.

GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.

More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.